Soluble ST2 as a Biomarker for Predicting Right Ventricular Dysfunction in Acute Pulmonary Embolism

• Published in: Journal of clinical medicine Vol. 13; no. 23; p. 7211
• Main Authors: Uyanik, Muhammet, Cinar, Ahmet, Gedikli, Omer, Tuna, Tibel, Avci, Bahattin
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.12.2024; MDPI
• Subjects: Asthma; Biological markers; Biomarkers; Blood gas analysis; Chronic obstructive pulmonary disease; Clinical outcomes; Complications and side effects; Creatinine; Embolisms; Fibroblasts; Health aspects; Heart failure; Heart ventricle, Right; Hemodynamics; Interleukin-1; Medical imaging; Mortality; Pulmonary embolism; Pulmonary embolisms; Risk assessment; Thrombosis; Variance analysis; Turkey; Japan; sST2; pulmonary embolism; pulmonary hypertension; PESI
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm13237211

Introduction: Suppression of Tumorigenicity 2 (ST2), a member of the interleukin-1 (IL-1) superfamily, is recognized as an important biomarker in inflammatory responses and cardiovascular diseases. Elevated serum levels of sST2 have prognostic value, particularly in cases of cardiac stress such as heart failure and acute pulmonary embolism (APE). We aimed to assess ST2 levels as a potential biomarker for right heart dysfunction in APE patients, particularly in the context of its limited predictive value for mortality and risk stratification. Methods: Patients diagnosed with APE confirmed via computed tomography pulmonary angiography (CTPA) were enrolled in this study. To ensure the specificity of sST2 elevation to APE, patients with other conditions known to cause elevated sST2 levels were excluded. Results: After pre-clinical evaluation, 66 patients diagnosed with APE who met the study criteria, and 62 healthy subjects in the control group, were included in this study. sST2 levels were positively correlated with APE. Conclusions: In patients diagnosed with APE, sST2 levels had high sensitivity. sST2 levels are elevated in APE and are associated with right ventricular dysfunction, but do not independently predict mortality or risk stratification based on Pulmonary Embolism Severity Index (PESI) scores.